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Coronary heart disease (CHD) is a complex disorder constituting a major health problem in Western societies. To
assess the genetic background of CHD, we performed a genomewide linkage scan in two study samples from the
genetically isolated population of Finland. An initial study sample consisted of family material from the northeastern
part of Finland, settled by a small number of founders ∼300 years ago. A second study sample originated from
the southwestern region of Finland, settled ∼2,000 years ago. Families were ascertained through probands exhibiting
premature CHD, defined as 150% stenosis of at least two coronary arteries at a young age, as verified by coronary
angiography. Both study samples and the pooled data set provided evidence for linkage in two chromosomal
regions. A region on chromosome 2q21.1-22 yielded two-point LOD scores of 3.2, 1.9, and 3.7, in the affected
sib-pair (ASP) analyses of the northeastern, southwestern, and pooled study samples. The corresponding multipoint
maximum-likelihood scores (MLSs) for these three study samples were 2.4, 1.3, and 3.0. In addition, a region on
chromosome Xq23-26 resulted in two-point LOD scores of 1.9, 3.5, and 2.9 and in multipoint MLSs of 3.4, 3.1,
and 2.5, respectively. In conclusion, this study identifies two loci likely to contribute to premature CHD: one on
chromosome 2q21.1-22 and another on chromosome Xq23-26.
Introduction
Coronary heart disease (CHD) is the leading cause of
death in the Western world. For effective treatment and
prevention, the complex molecular processes underlying
CHD, as well as factors predisposing to atherosclerosis,
should be identified. Clinical and epidemiological studies
have documented that several types of risk factors—such
as age, male sex, family history of myocardial infarction
(MI), increased serum total and low-density lipoprotein
cholesterol, decreased serum high-density lipoprotein
cholesterol, smoking history, and presence of diabetes
mellitus—predict the risk for atherogenesis (Rose 1964;
Kannel et al. 1971; Pooling Project Research Group
1978; Keys 1980; Pyo¨ra¨la¨ et al. 1987; Grundy et al.
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1990, 1998; Genest 1995; Wilson et al. 1998). Fur-
thermore, both inflammation linked with disadvanta-
geous plasma lipoprotein profile and chronic infections
have also been proposed as risk factors for CHD (Saikku
et al. 1988; Ridker et al. 1998; Noll 1998). Clearly, CHD
is a multifactorial disease in which risk factors tend to
cluster and interact in individuals and families to deter-
mine the level of risk. In addition, risk evaluation is
further complicated by the unknown relationship among
the underlying genetic and environmental risk factors.
The genetic background in common diseases merges
from combinations of risk alleles that, together with
environmental risk factors, lead to development of the
disease phenotype (Risch andMerikangas 1996; Collins
et al. 1997). Numerous studies have been carried out
to identify the genes that have alleles that can predispose
to CHD. Considerable evidence now indicates that var-
iation in genes encoding the apolipoprotein E (APOE
[MIM 107741]), apolipoprotein (a) (LPA [MIM
152200]), methyltetrahydrofolate reductase, and angi-
otensin-converting enzyme play a role in the develop-
ment of CHD (Kraft et al. 1996; Cambien et al. 1992;
Boushey et al. 1995; Wilson et al. 1996). However, the
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size and nature of the effects of these and other genes
influencing the risk of CHD are still largely unknown.
Evidence for genetic involvement in development of
CHD has been obtained from studies showing that fam-
ily history of CHD increases the risk for CHD (Rose
1964; Sholtz et al. 1975; Jousilahti et al. 1996) and also
from family studies estimating heritability of CHD to
be 56%–63% (Nora et al. 1980). To increase the impact
of genetic involvement and the possibilities of identi-
fying contributing predisposing genes, a careful selec-
tion of the study sample is advised (Lander and Schork
1994; Wright et al. 1999; Terwilliger and Go¨ring
2000a). Families with multiple affected individuals, ex-
treme phenotypes, subjects with early-onset disease, and
individuals originating from populations with restric-
ted genetic variation may increase the power to iden-
tify genetic risk factors by decreasing etiological
heterogeneity.
Genomewide linkage studies have been utilized to
identify loci for complex disorders and to search for
evidence of major gene effects. To date, however, no
genome scans have been reported for premature CHD.
We conducted a genomewide search for CHD loci in
well-documented families affected by premature CHD
that originate from the genetically isolated population
of Finland. A two-stage strategy was used, in which the
first stage of the scan, with an average marker interval
of 10 cM, was followed by fine mapping of interesting
regions. We also included two independent sample sets
in both stages of the scan: one from the late-settlement
region of Finland and the other from the early-settle-
ment region. This strategy enabled us to identify two
chromosomal regions, in both study samples, that may
harbor loci with alleles that predispose to premature
CHD: one on chromosome 2q21.1-22 and another on
chromosome Xq23-26.
Subjects and Methods
Subjects
A total of 156 families with at least two individuals
affected with premature CHD were collected. Of these,
89 “northeastern” families were collected as an initial
study sample in the Kuopio University Hospital. For
replication, an additional study sample of 67 “south-
western” families affected by premature CHD was col-
lected in the Turku University Hospital. The probands
for both study samples were selected from patients un-
dergoing elective coronary angiography for clinically
suspected coronary artery disease or from the angiog-
raphy register. Inclusion criteria in both northeastern
and southwestern study groups for the probands were
50% stenosis in two or three coronary arteries con-
firmed by coronary angiography, age !55 for males and
!65 for females. These age cutoffs take into account the
fact that, in general, women fall sick with CHD ∼10
years later than men, and they thus reflect the well-
known differences for CHD incidence between genders
(Mosca et al. 1997).
Two diagnostic criteria were used in the analyses. In
both of these criteria, the probands fulfilled the strict
diagnostic criteria for CHD and age described above,
but the criteria for the affected siblings varied. However,
every additional family member coded as “affected” ful-
filled the same age criteria as the proband (!55 years
for males and !65 years for females). In criterion I, the
CHD status of the affected sibling was determined as
2–3 vessel disease confirmed by coronary angiography
or verified myocardial infarction, using the following
criteria: (1) typical clinical symptoms; (2) definite elec-
trocardiogram finding, according to the Minnesota cod-
ing (WHO criteria) (Rose et al. 1982); and (3) elevated
levels of the creatine kinase (CK) enzyme and of its car-
diac isoenzyme CK-MB, and age !55 for males and !65
for females. In criterion II, the CHD status of the affected
sibling was determined as 1–3 vessel disease, confirmed
by coronary angiography, or verified myocardial infarc-
tion. In addition, in the southwestern group, positive
exercise-test information (i.e., at least a 2-mm ST seg-
ment depression) was available from six individuals, and
this information was used in determination of the af-
fection status of the affected sibling in diagnostic cri-
terion II. Families in which probands were affected with
familial hypercholesterolemia were excluded from the
study samples. In addition, 150 first-degree relatives of
affected individuals were genotyped to increase the
phase information in the statistical analysis (see below).
A total of 324 individuals were considered affected un-
der criterion I, and 364 were considered affected under
criterion II. The characteristics of these study samples
are shown in table 1.
The northeastern study was approved by the ethics
committee of the Kuopio University Hospitals and the
southwestern study by the ethics committee of the Turku
University Hospital. All subjects gave informed consent.
All the samples were taken according to the Helsinki
declaration.
Genotyping
DNA was extracted from EDTA blood, according to
a standard procedure. In stage I, a total of 303 micro-
satellite markers from a modified Weber screening set
(version 6) (Sheffield et al. 1995) were genotyped in 345
individuals from northeastern and 181 individuals from
southwestern CHD families. An additional 24 individ-
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Table 1
Characteristics of Northeastern-, Southwestern-, and Combined-Sample Families with CHD
Criterion
Sample
Origina
No. of
Affected
Subjects
No. of
Families
Average
Sibship
Size
Families
with
Two
Affected
Sibs
Families
with
Three
Affected
Sibs
Families
with
Four
Affected
Sibs
No. of
Male
Affecteds
No. of
Female
Affecteds
Families
with
Unaffected
Sibs
Families
with
Parental
Data
I NE 197 89 2.2 73 13 3 140 57 64 5
I SW 127 56 2.3 43 11 2 86 41 35 7
I All 324 145 2.2 116 24 5 226 98 99 12
II NE 202 89 2.3 71 12 6 142 60 61 5
II SW 162 67 2.4 43 20 4 106 56 31 10
II All 364 156 2.3 114 32 10 248 116 92 15
a NE p northeastern; SW p southwestern.
uals from eight additional southwestern CHD families
were genotyped in Stage II. In addition to genotyping
affected individuals, 150/158 first-degree relatives were
genotyped to increase phase information in stage I/II,
but were coded as unknown phenotype in the statistical
analysis. For the TDT and HRR analyses an additional
31 individuals were also genotyped from one south-
western and 11 northeastern singleton families in which
the singleton had a 2–3-vessel disorder and fulfilled the
age criteria.
For typing of markers in stage I of the project, flu-
orescently labeled PCR products were generated and
then were pooled into panels before electrophoresis was
done on ABI377 sequencers (PE Biosystems). Genotyp-
ing gels were analyzed in an automated systemdeveloped
at the Whitehead Institute/MIT Center for Genome Re-
search as previously described (Rioux et al. 1998). Mi-
crotiter-well PCR amplification of the markers was au-
tomated by a pipetting robot (Biomek 2000, Beckman).
In stage II, some areas resulting in maximum likeli-
hood scores (MLSs) 11—either in the two-point or mul-
tipoint affected-sib-pair (ASP) analysis of stage 1 (or
where marker informativeness was low)—were selected
for denser marker mapping. An additional 82 markers
were genotyped in stage II. The markers analyzed in
stage II were selected and mapped on the basis of in-
formation derived from the genetic maps of Cooperative
Human Linkage Center (Sheffield et al. 1995), Genethon
(Dib et al. 1996) or GeneMap ’99.
For typing of markers in stage II of the project, mi-
crotiter-well PCR amplification of the markers was au-
tomated by a pipetting robot (Biomek 2000, Beckman).
The fluorescently labeled PCR products were electro-
phoretically separated on an automated laser fluores-
cence DNA sequencer ABI 377 (PE Biosystems) with
Genescan version 2.1 fragment-analysis software. The
alleles were identified and verified by two persons in-
dependently for each marker, using the Genotyper pro-
gram (version 2.0, PE Biosystems).
Statistical Analyses
Mendelian segregation was checked using the Ped-
Check program (O’Connel and Weeks 1998). Because
the study material that we used consisted of small nu-
clear families with sparse phase information, we also
searched for possible genotyping errors using the “error”
option of the Mendel program, version 4.0 (kindly pro-
vided by K. Lange), in addition to the PedCheck pro-
gram. The program MAPMAKER/SIBS (Kruglyak and
Lander 1995) was used for two-point and multipoint
maximum likelihood IBD calculations. For all analyses,
the all independent pairs option was used when families
with more than two affected siblings were analyzed.
Two-point ASP analyses were also performed using the
SIBPAIR program (Kuokkanen et al. 1996) of the AN-
ALYZE package (Go¨ring and Terwilliger 2000a, 2000c)
to better address the problems associated with sibship
size (Davis and Weeks 1997). For each marker, the allele
frequencies were estimated from the total study sample
of the particular study group—that is, the northeastern
allele frequencies from the northeastern, the southwest-
ern from the southwestern, and the combined allele fre-
quencies from the combined study sample, respectively,
using a gene-counting method (Smith 1957; Go¨ring and
Terwilliger 2000b).
To test for possible linkage disequilibrium (LD) on the
linked regions on chromosomes 2 and X, family-based
tests of association, the TDT (Terwilliger and Ott 1992)
and/or haplotype-based haplotype relative risk (HRRR)
(Terwilliger and Ott 1992), were conducted in the 156
families. The TDT option of the GENEHUNTER (Krug-
lyak et al. 1996) program and the HRRLAMB (Terwil-
liger and Ott 1992) program of the ANALYZE package
(Go¨ring and Terwilliger 2000a; Go¨ring and Terwilliger
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2000c) were performed on chromosome 2. For chro-
mosome X, the TDT test is less useful, because this fam-
ily-based association test by definition handles only data
from heterozygous parents. Therefore, the possibility of
LD on chromosome X was examined using only the
HRRLAMB tool (Terwilliger and Ott 1992) of the AN-
ALYZE package (Go¨ring and Terwilliger 2000a; Go¨ring
and Terwilliger 2000c), in which homozygous parents
are used as well. Further, this program takes only ma-
ternal nontransmitted alleles as controls, but both trans-
mitted ones as case alleles. However, there was a large
number of missing parental genotypes in these study
samples. Therefore, to further test whether the allele fre-
quencies differ between case and control subjects with
one marker showing initial evidence of association in
the HRRLAMB analysis, we genotyped 94 controls who
were 155 years old and had no medical records of car-
diovascular disorders. A total of 47 of the control sub-
jects originated from northeastern Finland (30males and
17 females) and 47 (29 males and 18 females) from
southwestern Finland. The program DISLAMB (Ter-
williger 1995) was then used to test differences between
alleles of case and control subjects.
Potential genetic homogeneity between the northeast-
ern and southwestern study samples was first tested by
computing whether there are differences between the al-
lele frequencies by the GENPOP program. Then, genetic
distance between the two populations was computed on
the basis of the allele-frequency information on common
markers typed in unlinked regions in both study samples.
This analysis was performed using the POPDIST pro-
gram (Guldbrandtsen et al. 2000).
Results
The two study samples consisted of 89 families affected
by carefully defined premature CHD from the late-set-
tlement northeastern part of Finland and 67 families
from the early-settlement southwestern part. Thus, al-
together, 156 families affected by premature CHD were
included in the study. The strategy was to test the initial
findings from the northeastern study sample using an
independent sample which fulfilled similar strict phe-
notypic criteria for CHD. The early-settlement sample
provides an advantageous small founder size. In addi-
tion, the population of this region has an older genetic
history than that of the late-settlement region. Since the
late-settlement population originated from that of the
early-settlement region, a random sampling of a selected
set of CHD-predisposing genes could have taken place.
In the late-settlement population, the effective popula-
tion size is also smaller, and lifestyle and cultural risk
factors are less variable, making this a potentially more
powerful study population. Both samples, however,were
genotyped in both stages of the genome scan to monitor
possible regional differences in the genetic predisposition
to CHD between the southwestern and northeastern
parts of Finland and to allow for confounding effects of
likely gene-environment interactions.
In the initial genome scan (stage I), the genotype data
were analyzed using the strict diagnostic criterion I.
However, to better utilize all familial information about
CHD in fine mapping (stage II), we analyzed selected
regions using criterion II as well. Affected individuals
under criterion II fulfill the strict age limits, but include
individuals with one-vessel disorder or positive ECG
findings in the affected phenotype. Assuming that the
same risk allele is segregating in one family, this should
increase our power in fine mapping.
Stage I: Initial Genome Scan
Overall, we genotyped 303 markers in stage I. Mul-
tipoint ASP analyses of the northeastern sample showed
maximum-likelihood scores (MLS) 11.0 at 9 positions
on 7 chromosomes (2, 6, 10, 12, 15, 18, and X) (table
2). Multipoint MLSs 12.0 were observed at two loca-
tions on chromosome 2 (MLS 2.8), and on chromosome
X (2.2). In the southwestern sample, seven positions on
six chromosomes exhibited multipointMLSs 11.0: chro-
mosomes 2, 6, 9, 13, 21, and X (table 2), of which
chromosomes 2 (MLS 2.2) and X (3.1) exhibited the
MLSs 12. In the pooled analysis, only chromosome 2
(MLS 2.7) resulted in a multipoint MLS 12. These
pooled results for all chromosomes using diagnostic cri-
terion I are shown in table 2. In addition, the individual
markers with the two-point MLSs 11.0 in the north-
eastern, southwestern, or combined analyses of stage I
are indicated in table 3.
Table 3 further shows that the marker DXS6810 re-
sulted in a two-point MLS of 3.3 in the southwestern
study sample, whereas the MLS of this marker remained
!1 in the northeastern and pooled analyses. To test if
this difference is significant, we conducted a formal test
of equality of linkage evidence between these popula-
tions. For the marker DXS6810, we calculated as fol-
lows: 4.6 # [MLSsouthwest  MLSnortheast MLScombined],
distributed as x2 with 2 df, since each of the MLS sta-
tistics had two free parameters; thus, 4.6# [0
, resulting in a P value !.001.3.31 .19]p 14.35
Thus, the MLS of 3.3 in the southwestern study sam-
ple is significantly different from the results in the north-
eastern sample. However, in stage 2 (see below), when
more markers and individuals were genotyped in the
southwestern study sample, the MLS with this marker
decreased to 2.4 in the southwestern study sample using
criteria II, and theMLSs of the nearest markers remained
!1.0. The MLSs in the northeastern and the combined
group also remained !1.0 in stage 2.
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Table 3
Two-Point MLSs for Regional Samples
STAGE AND
CHROMOSOME MARKER
TWO-POINT MLS FOR SAMPLE
Northeastern Combined Southwestern
Stage I:a
1 D1S1660 1.41
1 D1S1665 1.04
2 D2S125 2.00 1.17
2 D2S1326 1.23 1.17
2 D2S1328 1.72 1.52
2 D2S1353 1.52
2 D2S1360 1.05 1.14
2 D2S1363 1.59 2.13
2 D2S1400 1.21
2 D2S1776 1.74
2 D2S1780 1.27
2 D2S338 2.21 1.69
2 D2S434 1.26
3 D3S2427 2.25 1.25
4 D4S408 1.44 1.84
6 D6S1027 1.30 1.18
6 D6S503 2.05 1.13
8 D8S1100 1.09 1.00
9 D9S1122 1.25
9 D9S910 1.77
10 D10S1412 1.30 1.27
10 D10S1426 1.21
10 D10S169 1.13
11 GATA67D03 1.35
12 D12S1090 1.02 1.88 1.09
12 D12S391 1.79 1.22
14 D14S588 1.11 1.52
14 D14S610 1.38 1.07
15 D15S153 2.19 1.07
16 D16S2619 1.01
18 GATA26C03 2.12 1.38
19 D19S589 1.20 1.23
20 D20S478 1.11 1.82
22 D22S446 1.38 1.01
22 D22S685 1.53 1.23
X DXS1047 2.46 1.67
X DXS6789 1.03 1.80 1.03
X DXS6800 2.75
X DXS6810 3.31
X DXS8041 1.32
Stage II:b
7 D7S1808 1.01 1.30
10 D10S570 1.31 1.31
10 D10S585 1.28 1.28
12 D12S345 1.01
22 D22S282 1.88 1.36
a Only markers resulting in two-point MLS 11 are shown.
b Additional two-point MLS 11 observed with stage II markers (except for
chromosomes 2 and X).
Stage II: Denser Map
In stage II, a total of 82 additional markers on chro-
mosomes 1 (1 marker), 2 (29), 3 (2), 4 (1), 5 (7), 6 (1),
7 (5), 10 (6), 11 (2), 12 (2), 22 (3), and X (23) were
genotyped in both sample sets. In the fine mapping, the
two-point MLSs of the additional markers, as well as
the multipoint MLSs, remained !2.0 in both sample sets,
separately and combined, for all regions except for chro-
mosomes 2 and X (tables 2 and 3).
Stage II: Chromosome 2
For chromosome 2, a total of 29 additional markers
were genotyped in both study samples using diagnostic
criteria I and II. The most significant results for chro-
Figure 1 Results on chromosome 2 of two-point and multipoint ASP analysis using the MAPMAKER/SIBS program. Bars indicate the
two-point results, and the solid line indicates the multipoint results. a, Results for the combined sample. b, Results for the northeastern study
sample. c, Results for the southwestern study sample.
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mosome 2 were obtained using diagnostic criterion II.
The results with criterion I were similar to results ob-
tained with criterion II but MLSs are slightly lower. The
results of the two-point and multipoint ASP analyses
using a high resolution marker map for chromosome 2
are shown in both study groups separately and combined
in fig. 1.
In the northeastern study sample, the highest two-
point MLS was 2.7 with the marker D2S284 and the
highest multipoint MLS was 2.4 (fig. 1b). In the repli-
cation material from southwestern Finland, the same
region showed an MLS of 2.3 in two-point ASP analysis
with the marker D2S2385 and an MLS of 1.3 in the
multipoint analysis (fig. 1c). The pooled analysis resulted
in MLSs of 3.0 with the marker D2S129 and of 3.0 in
multipoint analyses (fig. 1a).
We searched for potential linkage equilibrium (LD)
using TDT and HRRLAMB analyses in the combined
sample set with all markers genotyped for the interesting
region on chromosome 2. Marker D2S284 resulted in a
P value of .02 in the TDT analysis, but the numbers of
transmitted versus nontransmitted alleles (6 vs. 0) were
too small to draw any conclusions. Further, the
HRRLAMB analysis for this marker remained nonsig-
nificant. In summary, strong evidence for LD was not
observed with any of the loci tested on chromosome 2.
The average marker interval was 2.5 cM in this analyzed
39.5-cM region (fig. 1).
Stage II: Chromosome X
In stage II, 23 additional markers were genotyped in
both sample sets for the region identified in stage I on
chromosome X (fig. 2a–2c). As in the case of chromo-
some 2, the highest MLSs for chromosome X were ob-
tained using diagnostic criterion II. Worth noting is that,
for X-chromosomal markers, the MLS has only 1 df,
because one can only evaluate identity by descent of
chromosomes inherited from the mother’s side. So, an
affected sib pair can share either 0 or 1 allele IBD. In
the northeastern study sample, marker DXS6800 re-
sulted in the highest MLS of 2.5 in two-point maximum-
likelihood IBD analysis, whereas the maximum multi-
point MLS was 3.4 when criterion II was used (fig. 2b).
In the replication sample set from the southwestern Fin-
land, the highest two-point MLS was 3.5, with the
marker DXS1072, and the highest multipoint MLS was
3.1 in the ASP analysis (fig. 2c). However, the distance
between the multipoint peaks in two regional materials
was 23 cM (fig. 2b and 2c). In the combined analysis,
the two-point analysis produced an MLS of 2.8 with the
marker DXS1047. Furthermore, multipoint analysis of
the combined data set resulted in a relatively wide peak
of a 30-cM region with a maximum MLS of 2.5 (fig.
2a).
The possibility of LD on chromosome X was tested
using the HRRLAMB program which also uses infor-
mation from homozygous parents. The TDT test is less
informative when applied to genotype data from chro-
mosome X, since it only considers data from heterozy-
gous parents. A total of 22 markers, with an average
marker interval of 2.4 cM, were analyzed in the potential
region on chromosome X (fig. 2a–2c). One of the mark-
ers, DXS8053, showed initial hint of association using
the HRRLAMB program ( ). To test whether theP ! .01
allele frequencies differ between cases and controls with
this marker, we genotyped 94 unrelated controls, aged
155 years, who had no medical record of CHD: 47 in-
dividuals from northeastern (30 male and 17 female sub-
jects) and 47 (29 male and 18 female subjects) from
southwestern Finland. The distribution of the case and
control alleles, with marker DX8053, were as follows:
allele 1, 6 in case subjects versus 14 in control subjects;
allele 2, 218 versus 113; allele 3, 18 versus 16; and allele
4, 76 versus 41, resulting in a P value of .007 (the
table x2 test) using the DISLAMB program. Sep-2# n
arately, the southwestern families gave a P value of .04
with the southwestern control subjects and the north-
eastern families a P value of .2 with the northeastern
control subjects, respectively.
Analysis of the Dense Mapping Regions Using the
SIBPAIR Program
Since sibship size varies in the families with CHD in-
cluded in the study (table 1), we also performed a two-
point ASP analysis, using the SIBPAIR program of the
ANALYZE package, to better address the problems as-
sociated with sibship size (Davis and Weeks 1997). On
chromosome 2, the maximum two-point LOD scores
with the SIBPAIR program were 3.7 (marker D2S2313)
in the combined, 3.2 (D2S2313) in the northeastern, and
1.9 (D2S129) in the southwestern study groups. Marker
D2S129 is the same marker at which the combined data
set peaks in the MLS analysis, and the D2S1313 is its
adjacent marker (1.6 cM). On chromosome X, the high-
est two-point LOD scores were 2.9 (DXS1072), 1.9
(DXS1212), and 3.5 (DXS1072). Marker DXS1072 is
also the peak marker in the MLS analysis, and D2S1212
is located within the multipoint peak of the northeastern
sample. Thus, these results support those produced by
the MAPMAKER/SIBS program.
Testing for Genetic Heterogeneity between the Study
Samples
We pursued the possible genetic heterogeneity be-
tween the southwestern (early settlement) and north-
eastern (late settlement) samples by comparison of allele
frequencies and computation of the genetic distance be-
tween the two populations on the basis of the allele-
Figure 2 Results on chromosome X of two-point and multipoint ASP analysis using the MAPMAKER/SIBS program. Bars indicate the
two-point results, and the solid line indicates the multipoint results. a, Results for the combined sample. b, Results for the northeastern study
sample. c, Results for the southwestern study sample.
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frequency information on common markers typed in un-
linked regions in both study samples. The GENEPOP
analysis showed significant evidence of a difference be-
tween allele frequencies of multiple loci between the two
populations. The analysis of genetic distance was per-
formed using the POPDIST program (Guldbrandtsen et
al. 2000). In this analysis, Nei’s genetic distance,Ds (Nei
1984), was .009 (standard error [SE] .001) between the
study samples, providing some evidence for genetic het-
erogeneity between the southwestern and northeastern
study samples.
Discussion
Premature CHD is a major cause of morbidity in the
Western societies. In Finland, the occurrence of CHD is
one of the highest in the world (Tunstall-Pedoe et al.
1994), with the highest incidence in eastern Finland (Sal-
omaa et al. 1992; Jousilahti et al. 1998). In our ge-
nomewide scan for loci predisposing to prematureCHD,
we used two independent regional study samples, both
originating from the genetically isolated Finnish popu-
lation. The southwestern sample represents an early-set-
tlement region of Finland (∼2,000 years old) which also
has a less-heavy burden of environmental risk factors
for cardiovascular disorders (Vartiainen et al. 1994). The
northeastern study sample represents a late-settlement
region, founded ∼300 years ago by founders mostly orig-
inating from the early-settlement region (Varilo et al.
2000). This northeastern region has a higher prevalence
of CHD than other parts of Finland, probably because
of genetic factors combined with a clustering of envi-
ronmental risk factors for CHD (Vartiainen et al. 1994;
Jousilahti et al. 1998). We also tested for possible genetic
heterogeneity between the northeastern and southwest-
ern study samples by computing the genetic distance
between the two populations. Some evidence emerged
for genetic heterogeneity between the northeastern and
southwestern study samples, in accordance with the ear-
lier study by Kittles et al. (1998), in which a genetic
difference between the populations of these two regions
was implicated. The population in the late-settlement
region has gone through a bottleneck with restricted
number of founders and this might still be visible in the
allele frequencies of the late-settlement population. The
same loci were, however, identified in both populations
using angiographically confirmed severe-CHD index
cases and affected family members who fulfilled strict
diagnostic criteria for premature CHD in terms of the
well-defined clinical diagnosis and their age.
Two chromosomal regions, one on chromosome
2q21.1-22 and another on chromosome Xq23-26, re-
vealed evidence of linkage to premature CHD in both
separate and pooled analyses. The chromosomal region
on chromosome Xq23-26 is especially intriguing, be-
cause we also identified some evidence for LD with one
marker in this region.
The multipoint ASP analysis of the X-chromosomal
markers in the northeastern and southwestern study
samples resulted in two peaks separated by 23 cM. Con-
sequently, the peak produced in the pooled analysis re-
mained wide (∼30 cM). This could indicate the existence
of more than one X-chromosomal locus linked with
premature CHD or could reflect well-known problems
in multipoint analyses, such as genotyping and map
errors. Other explanations are also possible. The small
sample size of each study and, by definition, incorrect
parameters in linkage analyses of complex traits may
result in this kind of variation in the peak positions
(Hovatta et al. 1998; Ekelund et al. 2000). Minor dif-
ferences in the allele frequencies of markers and/or dis-
ease alleles could create differences in the informative-
ness of individual markers in separate study samples.
Interestingly, despite the presence of two multipoint
linkage peaks, only one marker (DXS8053) showed
some hint of linkage disequilibrium. This marker is lo-
cated in the middle of the 30-cM region, suggesting that
a single locus may be responsible for the linkage to CHD
in both study samples.
The full explanation for the higher frequency of pre-
mature CHD in men is still lacking. To some extent, a
hormonal shelter helps protect women from premature
CHD until menopause, since, after menopause,
women’s likelihood of having CHD increases dramat-
ically. This combined with higher load of cardiovascular
risk factors is likely to predispose men to premature
CHD (Jousilahti et al. 1999). Here, we found a region
linked to premature CHD on chromosome X. Most of
the linkage information emerges from men, because
65% of the affected individuals in the northeastern
study material and 70% in the southwestern material
were men. Since men are hemizygotes for disease alleles
on chromosomeX, they have higher probability to show
the effects of recessively acting X-chromosomal suscep-
tibility genes than do women. Although the background
of CHD is complex, undoubtedly also including other
genetic and environmental factors, this X-chromosomal
finding may offer a new starting point for future studies
on increased risk for premature CHD in men. Moni-
toring of intragenic single-nucleotide polymorphisms
(SNP) in this chromosomal region could help pinpoint
to the gene(s) associated with CHD.
On chromosome 2, a replication sample from the
southwestern part of Finland also showed evidence of
the potential linkage found in the northeastern sample
set, resulting in two-point MLS of 2.3. The combined
analysis produced an even higher MLS of 3.0 in two-
point analysis, with the marker D2S129 supporting fur-
ther the evidence for involvement of this chromosomal
region in CHD. No evidence of LD, however, could be
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detected. This may well indicate that none of the gen-
otyped markers is near enough to the causative gene.
In fact, in complex, multifactorial diseases such as
CHD, LD detected is likely to be restricted to much
smaller regions around the causative genes than in
monogenic diseases (Weiss 1995), even in genetic iso-
lates (Kruglyak 1999; Lonjou et al. 1999; Weiss and
Terwilliger, in press).
Earlier studies have shown that it is likely that genes
encoding the apolipoprotein E, apolipoprotein (a),
methyltetrahydrofolate reductase, and angiotensin-con-
verting enzyme participate in the CHD pathogenesis
(Kraft et al. 1996; Cambien et al. 1992; Boushey et al.
1995; Wilson et al. 1996). We therefore compared the
locations of these genes to our CHD scan results in the
northeastern, southwestern, and combined study groups
in stage 1 and 2 of the genome scan. However, none of
these genes were located in regions where we detected
MLSs 11.0 in stage 1 or 2. Neither were they located
on chromosomes 2 and X. These results suggest that
additional genes are likely to have effects on the com-
plex atherosclerotic process. We also looked for novel
CHD candidate genes on chromosome 2q21.1-22 and
Xq23-26. On chromosome Xq23-26, we found one po-
tentially interesting candidate; the angiotensin receptor
2 (AGTR2) gene resides in that region. The function of
the AGTR2 gene is largely unknown, but it is suggested
to play a role in the cardiovascular and central nervous
functions (Hein et al. 1995). In the identified region on
chromosome 2, the mitochondrial glycerophosphate de-
hydrogenase (GPD2) gene is indirectly a potentially in-
teresting candidate gene. Deficiency of the mitochon-
drial glycerophosphate dehydrogenase has been shown
to contribute to impaired glucose-stimulated insulin re-
lease in animal models of noninsulin-dependent diabetes
mellitus. However, no obvious CHD candidate genes
are located in this chromosomal region, suggesting that
a novel gene—or a gene the function of which in CHD
is not clear yet—may underlie the linkage. Further stud-
ies are warranted involving genotyping of SNPs for
these and other possible candidate genes in the regions
to search for allelic association with CHD and, finally,
to verify variants with functional significance.
In conclusion, CHD is a multifactorial disorder in
which numerous factors determine an individual’s cor-
onary risk. Our genome-scan data on severe premature
cases of familial CHD, collected from a population with
substantial environmental and genetic homogeneity
provided evidence for two chromosomal regions,
2q21.1-22 and Xq23-26, which are candidates to har-
bor novel genes predisposing to CHD.
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